Theravance Biopharma Inc
TBPH
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
32.5% downsideOvervalued by 32.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $827.94 Million |
|---|---|
| Enterprise Value | $599.34 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.1 |
| Beta | 0.19 |
| Outstanding Shares | 51,279,000 |
Return
| Return on Equity | 24.25% |
|---|---|
| Return on Assets | 24.25% |
| Return on Invested Capital | 18.63% |
Valuation & Multiples
| P/E Ratio | 7.19 |
|---|---|
| PEG | -11.29 |
| Price to Sales | 7.96 |
| Price to Book Ratio | 3.18 |
| Enterprise Value to Revenue | 5.46 |
| Enterprise Value to EBIT | 7.3 |
| Enterprise Value to Net Income | 5 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 11.9190▲ 1191.90% |
|---|---|
| Total Calls | 49,400▼ 53.57% |
| Total Puts | 588,800▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 98.98%▲ 0.82% |
|---|---|
| Total Invested | $808.36M▼ 12.81% |
| Investors Holding | 177▲ 6.00% |
ESG Score
No data
About Theravance Biopharma Inc
CEO: Rick Winningham Relevant Senate Committees
This committee assists tax-writing committees by providing official revenue estimates and analysis for all tax legislation, directly impacting corporate tax structures and overall fiscal policy relevant to pharmaceutical company profitability.
This committee controls taxation, trade, and entitlement spending, specifically influencing corporate tax policy and Medicare pricing, which are massive determinants of revenue and profitability for pharmaceutical companies.
This committee allocates federal spending, directly determining the budgets for health-related agencies like NIH, FDA, and the VA, which fund research, regulate products, and purchase drugs, profoundly impacting pharmaceutical companies.
This committee directly regulates the FDA (drug approval), NIH (research funding), and labor laws, all of which are critical to the research, development, approval, and operational costs of pharmaceutical companies.
This committee oversees antitrust laws, crucial for pharmaceutical mergers and acquisitions, and intellectual property (patents), which are fundamental to the market exclusivity and profitability of new drugs.